Truist Securities Maintains Buy on Collegium Pharmaceutical, Raises Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Les Sulewski has maintained a Buy rating on Collegium Pharmaceutical (NASDAQ:COLL) and increased the price target from $37 to $40.
February 26, 2024 | 1:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has reaffirmed its Buy rating on Collegium Pharmaceutical and raised the price target from $37 to $40.
The increase in price target by a reputable analyst firm like Truist Securities typically signals a strong bullish sentiment on the stock, suggesting a positive outlook on its future performance. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100